Selected article for: "bind affinity and high binding"
Author: Carabineiro, Sónia Alexandra Correia
Title: Applications of Gold Nanoparticles in Nanomedicine: Recent Advances in Vaccines †
  • Document date: 2017_5_22
    • ID: 0nz0qioh_35
    Snippet: The use of gold nanoparticles in HIV vaccine development has been recently reviewed by several authors [94] . After more than 30 years since the discovery of HIV in 1983, no effective vaccine is yet available [24, [95] [96] [97] . Some histocompatibility complex molecules expressed on the surface of HIV are potential targets for neutralizing antibodies [98] , as shown in Figure 4 . Among the few broadly neutralizing HIV monoclonal antibodies, 2G1.....
    Document: The use of gold nanoparticles in HIV vaccine development has been recently reviewed by several authors [94] . After more than 30 years since the discovery of HIV in 1983, no effective vaccine is yet available [24, [95] [96] [97] . Some histocompatibility complex molecules expressed on the surface of HIV are potential targets for neutralizing antibodies [98] , as shown in Figure 4 . Among the few broadly neutralizing HIV monoclonal antibodies, 2G12 is the only carbohydrate-directed that is able to recognize a cluster of high-mannose glycans on the viral envelope glycoprotein gp120 [95] . This type of glycan is thus envisaged as a target to develop an HIV vaccine capable of eliciting 2G12-like antibodies. Gold nanoparticles coated with self-assembled monolayers of synthetic oligomannosides, which are present in gp120, are able to bind 2G12 with high affinity and to interfere with 2G12/gp120 binding [95] . Thiol-terminated oligosaccharides have been attached on gold nanoparticles and have been used in attempts to develop an HIV vaccine [99] .

    Search related documents:
    Co phrase search for related documents
    • antibody elicit and high affinity: 1, 2
    • antibody elicit and HIV vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • effective vaccine and glycan type: 1
    • effective vaccine and gold nanoparticle: 1, 2, 3
    • effective vaccine and high affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • effective vaccine and high mannose: 1
    • effective vaccine and high mannose glycan: 1
    • effective vaccine and HIV discovery: 1, 2, 3, 4
    • effective vaccine and HIV monoclonal antibody: 1
    • effective vaccine and HIV surface: 1, 2, 3
    • effective vaccine and HIV vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • effective vaccine and HIV vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • glycan type and high affinity: 1, 2
    • glycan type and high mannose: 1, 2, 3, 4, 5, 6, 7, 8
    • glycan type and high mannose glycan: 1, 2, 3, 4, 5, 6, 7
    • glycan type and HIV discovery: 1
    • glycan type and HIV surface: 1
    • glycan type and HIV vaccine: 1, 2
    • glycan type and HIV vaccine development: 1